Q2 FY2026 · ended Jun 30, 2026 · Revenue $276,218, +19.3% YoY · Filed Aug 18, 2026
Cannapharmarx, Inc. (CPMD) files with the SEC under industry code 2834, Pharmaceutical Preparations. In Q2 of fiscal 2026, the quarter ended Jun 30, 2026, it reported revenue of $276,218 and a net loss of $1.9 million. Free cash flow was -$182,487. As of Jun 30, 2026 it held $555 in cash and investments and $5.8 million in total debt.
Revenue
$276,218
+19.3% vs year-ago quarter
Net income
$-1.91M
-35.1% vs year-ago quarter
Operating cash flow
$-127,369
+71.5% vs year-ago quarter
Free cash flow
$-182,487
-1.4% vs prior quarter
EPS
$0.00
Dividend per share
None
Shares outstanding
708.69M
+7.0% vs year-ago quarter
Net cash
$-5.78M
Q2 FY2026
Operating margin
-170.1%
TTM
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- CPMD (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Mountain View County
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1081938
- Former names
- GOLDEN DRAGON HOLDING CO. (until Oct 27, 2014); CCVG, INC. (until Jan 12, 2011); CONCORD VENTURES, INC. (until Nov 17, 2010); CAVION TECHNOLOGIES INC (until Jul 25, 2007)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $276,218 | $627,462 | $138,630 | $656,606 | $231,608 |
| Operating income | -$378,831 | -$682,343 | -$893,553 | -$935,646 | -$840,980 |
| Net income | -$1.9M | -$382,021 | -$7.5M | -$1.5M | -$1.4M |
| Diluted EPS | $0.00 | $0.00 | — | $0.00 | $0.00 |
| Operating cash flow | -$127,369 | -$243,656 | $1.1M | -$802,700 | -$446,463 |
| Free cash flow | -$182,487 | — | — | — | — |
| Total assets | $6.9M | $6.6M | $7.0M | $11.6M | $11.5M |
| Total liabilities | $37.7M | $36.9M | $37.2M | $34.1M | $34.0M |
| Stockholders' equity | -$30.8M | -$30.3M | -$30.2M | -$22.5M | -$22.6M |
| Cash and investments | $555 | — | $1,804 | — | — |
| Total debt | $5.8M | $5.9M | $6.0M | — | — |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Aug 18, 2026 | Jun 30, 2026 |
| 10-Q | Quarterly report | May 20, 2026 | Mar 31, 2026 |
| 10-K | Annual report | Mar 31, 2026 | Dec 31, 2025 |
| 8-K |
Current report
Officer or director change, Other events
|
Jan 13, 2026 | Jan 8, 2026 |
| 8-K |
Current report
Other events
|
Dec 18, 2025 | Dec 12, 2025 |
| 10-Q | Quarterly report | Nov 14, 2025 | Sep 30, 2025 |
All 365 Cannapharmarx, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.